Bio-Rad to Acquire Digital PCR Developer Stilla Technologies

Bio-Rad Laboratories (Hercules, CA, USA) has entered into a binding offer to purchase all equity interests in Stilla Technologies (Villejuif, France). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.

With operations in France and the U.S., Stilla develops and markets next-generation digital PCR instruments, consumables, and assays. The company’s Nio family of all-in-one digital PCR systems aids the development of a wide range of genetic tests and molecular assays across multiple applications including liquid biopsy for oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.

"Stilla’s next-generation digital PCR solutions would make a compelling and complementary addition to Bio-Rad’s best-in-class digital PCR portfolio,” said Norman Schwartz, CEO of Bio-Rad Laboratories. “Once closed, the acquisition will support our strategy to further expand our business into applied research and clinical diagnostics where customers expect a higher degree of automation and throughput capabilities.”

“Together with our planned launch of Bio-Rad’s QX Continuum system, the Stilla platform would allow us to serve the full range of digital PCR applications and help us meet the evolving needs of customers in genomics research and applied science,” added Jim Barry, EVP and President of Bio-Rad’s Life Science Group.

“We are thrilled with the prospect of joining Bio-Rad, a leader in the field of digital PCR,” stated Rémi Dangla, CEO of Stilla Technologies. “With Stilla’s passion for product development and Bio-Rad’s extensive life science expertise, operational excellence, and global reach, together we can bring substantial value to the work of applied research and biopharma customers around the globe.”

Related Links:
Bio-Rad Laboratories
Stilla Technologies

Visit expo >

Gold Member

Fully Automated Cell Density/Viability Analyzer

BioProfile FAST CDV

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Luteinizing Hormone Assay

DRG LH-Serum ELISA Kit

New

Total Thyroxine Assay

Total Thyroxine CLIA Kit